Clinical Trial Detail

NCT ID NCT02339571
Title Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Sargramostim

Nivolumab

Ipilimumab

Age Groups: adult

No variant requirements are available.